Attune Pharmaceuticals
June 2018, Series B Attune is a clinical-stage biotechnology company focused on novel small-molecule therapeutics for rare diseases. Attune's lead drug is in clinical trials for the treatment of HAE and a second program is focused on complement-mediated diseases. Investors include Venrock, RTW Investments, RA Capital, Tavistock and Tang Capital.
Total raised: $23M

Investors 2

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
23.01.2019Series B$23M--

Mentions in press and media 5

24.01.2019Attune Pha...Attune Pharmaceuticals, Inc.,
23.01.2019Attune Pha...NEW YORK, Jan. 23, 2019 (GLOBE...--citybizlis...
23.01.2019Attune Pha...Attune Pharmaceuticals raised ...Biotech-fiercebiot...
23.01.2019Term Sheet...CRYPTO CAPITAL Good morning,
23.01.2019Daily raised $2M; Chowbus...-Kristin